Stifel Financial’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Stifel Financial’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-15,500	Closed	-$57K	–	2822
2017 Q4	$57K	Buy	15,500 +1,540	+11%	+$6.3K	﹤0.01%	2584
2017 Q3	$57K	Hold	13,960	–	–	﹤0.01%	2514
2017 Q2	$52K	Hold	13,960	–	–	﹤0.01%	2495
2017 Q1	$58K	Hold	13,960	–	–	﹤0.01%	2464
2016 Q4	$60K	Sell	13,960 -1	-0%	-$6	﹤0.01%	2393
2016 Q3	$137K	Hold	13,961	–	–	﹤0.01%	2263
2016 Q2	$79K	Hold	13,961	–	–	﹤0.01%	2399
2016 Q1	$106K	Hold	13,961	–	–	﹤0.01%	2102
2015 Q4	$186K	Hold	13,961	–	–	﹤0.01%	2139
2015 Q3	$230K	Hold	13,961	–	–	﹤0.01%	1957
2015 Q2	$313K	Hold	13,961	–	–	﹤0.01%	1931
2015 Q1	$137K	Hold	13,961	–	–	﹤0.01%	2169
2014 Q4	$159K	Buy	+13,961	New	+$152K	﹤0.01%	2141

Stifel Financial's CASC Position: Q1 2018 in Review

Stifel Financial sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 15,500 shares — an estimated $57K sold.

Stifel Financial first reported a position in CASC in Q4 2014 and held it in 13 quarters. The position peaked at $313K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Stifel Financial reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Stifel Financial sold 15,500 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $57K.
Stifel Financial first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
Stifel Financial's Cascadian Therapeutics, Inc. position peaked at $313K in Q2 2015.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Stifel Financial's 13F filing for Q1 2018, filed 11 May 2018.